Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.
Hiramatsu
K
K
Hanaki
H
H
Ino
T
T
Yabuta
K
K
Oguri
T
T
Tenover
F C
FC
D000617:Aminoglycosides; D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003982:Dibekacin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008297:Male; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D018633:Pulmonary Atresia / Q000150:complications / Q000601:surgery; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D013407:Sulbactam / Q000627:therapeutic use; D014640:Vancomycin / Q000494:pharmacology* / Q000627:therapeutic use*; D014947:Wounds and Injuries / Q000382:microbiology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003982:Dibekacin; D014640:Vancomycin; D000667:Ampicillin; C031986:arbekacin; D013407:Sulbactam